nid,exclude,study_id,author,text_description,source,location_id,location_id2,location_name,piv,prim_inf_var,variant,variant_b1351,symptom_severity,symptom_severity_description,severity,IHME_symptom_classification,severe_vs_all,severe,moderate,mild,asymptomatic,sex_id,age_start,age_end,age_mean,over_65,sample_size,efficacy_mean,efficacy_lower,efficacy_upper,pinf,average_time_since_infection,start_interval,end_interval,start_end_int,Period reported in the study,past_infection_evaluation,quality_rating,events_vaccine,events_control,ss_vaccine,ss_control,hiv_flag,obesity_flag,comorbidity_flag,ethnicity_flag,race_flag,dose_flag,high_risk_flag,infectious_flag,notes,extractor_id
,0,1,Berec L,medrix- Czech VE/ previous infection immunity whole country retrospective study,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,1,mixed variant,all variant,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,,,0.99,0.98,0.99,1,,0,8,0_8,Weeks after infection,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 65. ,han20
,0,1,Berec L,medrix- Czech VE/ previous infection immunity whole country retrospective study,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,1,mixed variant,all variant,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,,,0.97,0.965,0.975,1,,9,16,9_16,Weeks after infection,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 65. ,han20
,0,1,Berec L,medrix- Czech VE/ previous infection immunity whole country retrospective study,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,1,mixed variant,all variant,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,,,0.91,0.905,0.915,1,,17,24,17_24,Weeks after infection,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 65. ,han20
,0,1,Berec L,medrix- Czech VE/ previous infection immunity whole country retrospective study,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,1,mixed variant,all variant,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,,,0.92,0.915,0.925,1,,25,32,25_32,Weeks after infection,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 65. ,han20
,0,1,Berec L,medrix- Czech VE/ previous infection immunity whole country retrospective study,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,1,mixed variant,all variant,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,,,0.9,0.895,0.905,1,,33,40,33_40,Weeks after infection,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 65. ,han20
,0,1,Berec L,medrix- Czech VE/ previous infection immunity whole country retrospective study,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,1,mixed variant,all variant,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,,,0.84,0.835,0.845,1,,41,48,41_48,Weeks after infection,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 65. ,han20
,0,1,Berec L,medrix- Czech VE/ previous infection immunity whole country retrospective study,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,1,mixed variant,all variant,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,,,0.79,0.78,0.8,1,,49,56,49_56,Weeks after infection,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 65. ,han20
,0,1,Berec L,medrix- Czech VE/ previous infection immunity whole country retrospective study,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,1,mixed variant,all variant,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,,,0.71,0.685,0.72,1,,57,64,57_64,Weeks after infection,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 65. ,han20
,0,1,Berec L,medrix- Czech VE/ previous infection immunity whole country retrospective study,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,1,mixed variant,all variant,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,,,0.71,0.65,0.78,1,,65,72,65_72,Weeks after infection,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 65. ,han20
,0,2,Goldberg Y,medrix- Israel previous inffuction immunity vs VE immunity ,https://academic.oup.com/aje/advance-article/doi/10.1093/aje/kwac060/6556183?login=false,85,85,Israel,1,Ancestral,B.1.1.7,,infection,positive COVID-19 PCR 3 months after 1st infection,infection,infection,,1,1,1,1,3,16,80,,,,0.948,0.944,0.951,0,,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 80. ,han20
,0,2,Goldberg Y,medrix- Israel previous inffuction immunity vs VE immunity ,https://academic.oup.com/aje/advance-article/doi/10.1093/aje/kwac060/6556183?login=false,85,85,Israel,1,Ancestral,B.1.1.7,,severe,hospitalization with positive COVID-19 PCR 3 months after 1st infection,hosp,severe,,1,0,0,0,3,16,80,,,,0.941,0.919,0.957,0,,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 80. ,han20
,0,2,Goldberg Y,medrix- Israel previous inffuction immunity vs VE immunity ,https://academic.oup.com/aje/advance-article/doi/10.1093/aje/kwac060/6556183?login=false,85,85,Israel,1,Ancestral,B.1.1.7,,severe,death due to covid 19,death,severe,,1,0,0,0,3,16,80,,,,0.964,0.925,0.983,0,,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 80. ,han20
,0,3,Hansen C,Lancet- Denmark previous infection immunity,https://www.sciencedirect.com/science/article/pii/S0140673621005754?casa_token=pSL73c9XKCMAAAAA:8z-wz_dodqU5OeQ4mauRrO75Hz1MLLXJW9nF06adogbUB78Ds2d2N7rvak4FyEeLVqh-PASamN0,78,78,Denmark,1,Ancestral,Ancestral,,infection,new positive test at least 90 days later.,infection,infection,,1,1,1,1,3,18,65,,,,0.788,0.749,0.821,0,,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 65. ,han20
,0,3,Hansen C,Lancet- Denmark previous infection immunity,https://www.sciencedirect.com/science/article/pii/S0140673621005754?casa_token=pSL73c9XKCMAAAAA:8z-wz_dodqU5OeQ4mauRrO75Hz1MLLXJW9nF06adogbUB78Ds2d2N7rvak4FyEeLVqh-PASamN0,78,78,Denmark,1,Ancestral,Ancestral,,infection,new positive test at least 90 days later.,infection,infection,,1,1,1,1,3,18,65,,,,0.793,0.744,0.833,1,,12,24,12_24,Weeks after infection,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,"Age end >= 65. analysis ended at +25 weeks, range included as 25-32 for sake of the analysis",han20
,0,3,Hansen C,Lancet- Denmark previous infection immunity,https://www.sciencedirect.com/science/article/pii/S0140673621005754?casa_token=pSL73c9XKCMAAAAA:8z-wz_dodqU5OeQ4mauRrO75Hz1MLLXJW9nF06adogbUB78Ds2d2N7rvak4FyEeLVqh-PASamN0,78,78,Denmark,1,Ancestral,Ancestral,,infection,new positive test at least 90 days later.,infection,infection,,1,1,1,1,3,18,65,,,,0.777,0.709,0.829,1,,25,32,25_32,Weeks after infection,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,"Age end >= 65. analysis ended at +25 weeks, range included as 25-32 for sake of the analysis",han20
,0,4,Kim P ,CID- previous infection immunity vs Delta,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab999/6448857?login=true,102,102,United States,1,Ancestral,B.1.617.2,,infection,positive covid pcr occurring?>90 days after initial testing,infection,infcetion,,1,1,1,1,3,17,65,,,,0.854,0.8,0.893,0,,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 65. ,han20
,0,4,Kim P ,CID- previous infection immunity vs Delta,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab999/6448857?login=true,102,102,United States,1,Ancestral,B.1.617.2,,"Mild, Moderate + Severe",symptomatic individuals with positive covid pcr occurring?>90 days after initial testing,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,17,65,,,,0.882,0.829,0.919,0,,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 65. ,han20
,0,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,Ancestral,B.1.1.7,,"Mild, Moderate + Severe", only documented infections with a PCR cycle threshold (Ct) value of 30 or less were included as cases in our study.,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,,,0.953,0.66,0.993,0,,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70. ",han20
,0,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,Ancestral,B.1.351,,"Mild, Moderate + Severe", only documented infections with a PCR cycle threshold (Ct) value of 30 or less were included as cases in our study.,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,,,0.854,0.724,0.922,0,,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70. ",han20
,0,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,mixed variant,B.1.617.2,,"Mild, Moderate + Severe", only documented infections with a PCR cycle threshold (Ct) value of 30 or less were included as cases in our study.,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,,,0.902,0.819,0.946,0,,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70. ",han20
,0,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,mixed variant,B.1.1.529,,"Mild, Moderate + Severe", only documented infections with a PCR cycle threshold (Ct) value of 30 or less were included as cases in our study.,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,,,0.619,0.48,0.72,0,,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70. ",han20
,0,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,Ancestral,B.1.1.7,,severe,hospitalization or death caused by reinfection,hosp&death,severe,,1,0,0,0,3,20,70,,,,0.694,0.01,0.962,0,,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70. Lower bound was originally -1.43, changed to 0.01 to include in the logit model",han20
,0,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,Ancestral,B.1.351,,severe,hospitalization or death caused by reinfection,hosp&death,severe,,1,0,0,0,3,20,70,,,,0.88,0.507,0.971,0,,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70. ",han20
,0,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,mixed variant,B.1.617.2,,severe,hospitalization or death caused by reinfection,hosp&death,severe,,1,0,0,0,3,20,70,,,,0.999,0.433,0.999,0,,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70. ",han20
,0,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,mixed variant,B.1.1.529,,severe,hospitalization or death caused by reinfection,hosp&death,severe,,1,0,0,0,3,20,70,,,,0.878,0.475,0.971,0,,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70. ",han20
,0,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,Ancestral,B.1.1.7,,infection, only documented infections with a PCR cycle threshold (Ct) value of 30 or less were included as cases in our study.,infection,infection,,1,1,1,1,3,20,70,,,,0.894,0.226,0.985,1,,12,32,12_32,Weeks after infection,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70.  period ends at 56+ weeks, time interval included as 57-70 for sake of the analysis",han20
,0,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,Ancestral,B.1.1.7,,infection, only documented infections with a PCR cycle threshold (Ct) value of 30 or less were included as cases in our study.,infection,infection,,1,1,1,1,3,20,70,,,,0.91,0.345,0.988,1,,33,56,33_56,Weeks after infection,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70.  period ends at 56+ weeks, time interval included as 57-70 for sake of the analysis",han20
,1,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,Ancestral,B.1.1.7,,infection, only documented infections with a PCR cycle threshold (Ct) value of 30 or less were included as cases in our study.,infection,infection,,1,1,1,1,3,20,70,,,,NA,NA,NA,1,,57,70,57_70,Weeks after infection,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70.  period ends at 56+ weeks, time interval included as 57-70 for sake of the analysis",han20
,0,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,Ancestral,B.1.351,,infection, only documented infections with a PCR cycle threshold (Ct) value of 30 or less were included as cases in our study.,infection,infection,,1,1,1,1,3,20,70,,,,0.926,0.767,0.976,1,,12,32,12_32,Weeks after infection,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70.  period ends at 56+ weeks, time interval included as 57-70 for sake of the analysis",han20
,0,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,Ancestral,B.1.351,,infection, only documented infections with a PCR cycle threshold (Ct) value of 30 or less were included as cases in our study.,infection,infection,,1,1,1,1,3,20,70,,,,0.812,0.655,0.898,1,,33,56,33_56,Weeks after infection,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70.  period ends at 56+ weeks, time interval included as 57-70 for sake of the analysis",han20
,1,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,Ancestral,B.1.351,,infection, only documented infections with a PCR cycle threshold (Ct) value of 30 or less were included as cases in our study.,infection,infection,,1,1,1,1,3,20,70,,,,NA,NA,NA,1,,57,70,57_70,Weeks after infection,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70.  period ends at 56+ weeks, time interval included as 57-70 for sake of the analysis",han20
,0,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,mixed variant,B.1.617.2,,infection, only documented infections with a PCR cycle threshold (Ct) value of 30 or less were included as cases in our study.,infection,infection,,1,1,1,1,3,20,70,,,,0.934,0.876,0.965,1,,12,32,12_32,Weeks after infection,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70.  period ends at 56+ weeks, time interval included as 57-70 for sake of the analysis",han20
,0,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,mixed variant,B.1.617.2,,infection, only documented infections with a PCR cycle threshold (Ct) value of 30 or less were included as cases in our study.,infection,infection,,1,1,1,1,3,20,70,,,,0.911,0.833,0.953,1,,33,56,33_56,Weeks after infection,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70.  period ends at 56+ weeks, time interval included as 57-70 for sake of the analysis",han20
,0,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,mixed variant,B.1.617.2,,infection, only documented infections with a PCR cycle threshold (Ct) value of 30 or less were included as cases in our study.,infection,infection,,1,1,1,1,3,20,70,,,,0.871,0.594,0.959,1,,57,70,57_70,Weeks after infection,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70.  period ends at 56+ weeks, time interval included as 57-70 for sake of the analysis",han20
,0,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,mixed variant,B.1.1.529,,infection, only documented infections with a PCR cycle threshold (Ct) value of 30 or less were included as cases in our study.,infection,infection,,1,1,1,1,3,20,70,,,,0.64,0.547,0.714,1,,12,32,12_32,Weeks after infection,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70.  period ends at 56+ weeks, time interval included as 57-70 for sake of the analysis",han20
,0,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,mixed variant,B.1.1.529,,infection, only documented infections with a PCR cycle threshold (Ct) value of 30 or less were included as cases in our study.,infection,infection,,1,1,1,1,3,20,70,,,,0.472,0.375,0.554,1,,33,56,33_56,Weeks after infection,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70.  period ends at 56+ weeks, time interval included as 57-70 for sake of the analysis",han20
,0,5,Altarawneh H ,NEJM- Qatar previous infection immunity for several variants,https://www.nejm.org/doi/full/10.1056/NEJMc2200133,151,151,Qatar,1,mixed variant,B.1.1.529,,infection, only documented infections with a PCR cycle threshold (Ct) value of 30 or less were included as cases in our study.,infection,infection,,1,1,1,1,3,20,70,,,,0.596,0.507,0.67,1,,57,70,57_70,Weeks after infection,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >= 70.  period ends at 56+ weeks, time interval included as 57-70 for sake of the analysis",han20
,0,6,Rane M,medrix- VE delta vs previous infection imunity,https://www.medrxiv.org/content/10.1101/2022.02.21.22271298v1.full.pdf,102,102,United States,1,mixed variant,B.1.617.2,,"Mild, Moderate + Severe","We defined symptomatic COVID-19 as SARS-CoV-2 positive patients who exhibited at least one of these symptoms: fever, oxygen saturation < 95%, chills, cough, headache, fatigue, myalgia, sore throat, chest tightness, shortness of breath, loss All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: https://doi.org/10.1101/2022.02.21.22271298; this version posted February 22, 2022. The copyright holder for this preprint of sense of taste and smell, nausea, vomiting, diarrhea, chest pain, confusion/altered mental state",Symptomatic,"Mild, Moderate + Severe",,1,1,1,1,3,12,80,,,,0.9,0.87,0.93,2,34,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age end > 80.,han20
,0,7,Smid M,medrix- Czech VE/ previous infection Omicron vs delta,https://www.medrxiv.org/content/10.1101/2022.02.24.22271396v1.full.pdf,47,47,Czechia,1,mixed variant,B.1.1.529,,severe,"hospital admission of a person, who tested positive on a PCR test, within two weeks after the confirmed infection or earlier",hosp,severe,,1,0,0,0,3,5,80,,,,0.87,0.73,0.94,1,,2,24,2_24,Weeks after infection,Confirmed infection registered in National Health System,Poor,0,0,0,0,0,0,0,0,0,0,0,0,Age end at 80+. study period ends at 6 months + period included as 25- 52,han20
,0,7,Smid M,medrix- Czech VE/ previous infection Omicron vs delta,https://www.medrxiv.org/content/10.1101/2022.02.24.22271396v1.full.pdf,47,47,Czechia,1,mixed variant,B.1.1.529,,severe,"hospital admission of a person, who tested positive on a PCR test, within two weeks after the confirmed infection or earlier",hosp,severe,,1,0,0,0,3,5,80,,,,0.92,0.86,0.96,1,,25,52,25_52,Weeks after infection,Confirmed infection registered in National Health System,Poor,0,0,0,0,0,0,0,0,0,0,0,0,Age end at 80+. study period ends at 6 months + period included as 25- 52,han20
,0,7,Smid M,medrix- Czech VE/ previous infection Omicron vs delta,https://www.medrxiv.org/content/10.1101/2022.02.24.22271396v1.full.pdf,47,47,Czechia,1,mixed variant,B.1.617.2,,severe,"hospital admission of a person, who tested positive on a PCR test, within two weeks after the confirmed infection or earlier",hosp,severe,,1,0,0,0,3,5,80,,,,0.99,0.98,0.99,1,,2,24,2_24,Weeks after infection,Confirmed infection registered in National Health System,Poor,0,0,0,0,0,0,0,0,0,0,0,0,Age end at 80+. study period ends at 6 months + period included as 25- 52,han20
,0,7,Smid M,medrix- Czech VE/ previous infection Omicron vs delta,https://www.medrxiv.org/content/10.1101/2022.02.24.22271396v1.full.pdf,47,47,Czechia,1,mixed variant,B.1.617.2,,severe,"hospital admission of a person, who tested positive on a PCR test, within two weeks after the confirmed infection or earlier",hosp,severe,,1,0,0,0,3,5,80,,,,0.95,0.93,0.96,1,,25,52,25_52,Weeks after infection,Confirmed infection registered in National Health System,Poor,0,0,0,0,0,0,0,0,0,0,0,0,Age end at 80+. study period ends at 6 months + period included as 25- 52,han20
,0,7,Smid M,medrix- Czech VE/ previous infection Omicron vs delta,https://www.medrxiv.org/content/10.1101/2022.02.24.22271396v1.full.pdf,47,47,Czechia,1,mixed variant,B.1.1.529,,infection,"SARS73 CoV-2 infection defined as a PCR-confirmed positive test of 74 any type of sample regardless of the presence of symptoms,",infection,infection,,1,1,1,1,3,5,80,,,,0.68,0.68,0.69,1,,2,24,2_24,Weeks after infection,Confirmed infection registered in National Health System,Poor,0,0,0,0,0,0,0,0,0,0,0,0,Age end at 80+. study period ends at 6 months + period included as 25- 52,han20
,0,7,Smid M,medrix- Czech VE/ previous infection Omicron vs delta,https://www.medrxiv.org/content/10.1101/2022.02.24.22271396v1.full.pdf,47,47,Czechia,1,mixed variant,B.1.1.529,,infection,"SARS73 CoV-2 infection defined as a PCR-confirmed positive test of 74 any type of sample regardless of the presence of symptoms,",infection,infection,,1,1,1,1,3,5,80,,,,0.13,0.1,0.14,1,,25,52,25_52,Weeks after infection,Confirmed infection registered in National Health System,Poor,0,0,0,0,0,0,0,0,0,0,0,0,Age end at 80+. study period ends at 6 months + period included as 25- 52,han20
,0,7,Smid M,medrix- Czech VE/ previous infection Omicron vs delta,https://www.medrxiv.org/content/10.1101/2022.02.24.22271396v1.full.pdf,47,47,Czechia,1,mixed variant,B.1.617.2,,infection,"SARS73 CoV-2 infection defined as a PCR-confirmed positive test of 74 any type of sample regardless of the presence of symptoms,",infection,infection,,1,1,1,1,3,5,80,,,,0.95,0.94,0.96,1,,2,24,2_24,Weeks after infection,Confirmed infection registered in National Health System,Poor,0,0,0,0,0,0,0,0,0,0,0,0,Age end at 80+. study period ends at 6 months + period included as 25- 52,han20
,0,7,Smid M,medrix- Czech VE/ previous infection Omicron vs delta,https://www.medrxiv.org/content/10.1101/2022.02.24.22271396v1.full.pdf,47,47,Czechia,1,mixed variant,B.1.617.2,,infection,"SARS73 CoV-2 infection defined as a PCR-confirmed positive test of 74 any type of sample regardless of the presence of symptoms,",infection,infection,,1,1,1,1,3,5,80,,,,0.83,0.82,0.84,1,,25,52,25_52,Weeks after infection,Confirmed infection registered in National Health System,Poor,0,0,0,0,0,0,0,0,0,0,0,0,Age end at 80+. study period ends at 6 months + period included as 25- 52,han20
,0,8,Abu-Raddad L,Lancet- Qatar reinfection immunity,https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00141-3/fulltext,151,151,Qatar,1,Ancestral,Ancestral,,infection,Reinfection was defined as a PCR positive result in an individual who had a prior infection that had cleared. All SARS-CoV-2 antibody-positive persons in Qatar with at least one PCR-positive swab that occurred ?14 days after the first-positive antibody test were considered suspected cases of reinfection,infection,infection,,1,1,1,1,3,10,74,,,,0.927,0.913,0.939,2,17,,,,,Antibody testing,Fair,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,9,Hall V,Lancet- reinfection immunity SIREN,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00675-9/fulltext,95,95,United Kingdom,1,Ancestral,B.1.1.7,,infection,A possible reinfection was defined as a participant with two positive PCR samples 90 or more days apart (based on previous national surveillance analysis) or an antibody positive participant with a new positive PCR test at least 4 weeks after the first antibody-positive result,infection,infection,,1,1,1,1,3,18,65,,,,0.84,0.81,0.87,2,29,,,,,Antibody testing,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 65. ,han20
,0,10,Hall V,NEJM- reinfection immunity all variants,https://www.nejm.org/doi/full/10.1056/NEJMoa2118691,102,102,United Kingdom,1,all variant,all variant,,infection,"SARS-CoV-2 infection, irrespective of the participant’s symptom status  (two PCR-positive samples ?90 days apart)",infection,infection,,1,1,1,1,3,25,65,,,,0.86,0.81,0.89,1,,0,51,0_51,Weeks after infection,Antibody testing and/or confirmed infection through PCR,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 65 Age start < 25. ,han20
,0,10,Hall V,NEJM- reinfection immunity all variants,https://www.nejm.org/doi/full/10.1056/NEJMoa2118691,102,102,United Kingdom,1,all variant,all variant,,infection,"SARS-CoV-2 infection, irrespective of the participant’s symptom status  (two PCR-positive samples ?90 days apart)",infection,infection,,1,1,1,1,3,25,65,,,,0.69,0.38,0.84,1,,52,104,52_104,Weeks after infection,Antibody testing and/or confirmed infection through PCR,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 65 Age start < 25. ,han20
,0,11,Pilz S,EJCI- Austria previous infection immunity,https://onlinelibrary.wiley.com/doi/10.1111/eci.13520,75,75,Austria,1,Ancestral,Ancestral,,infection,"Patients who had a positive polymerase chain reaction (PCR) test during both, the first and second infection wave are referred to here as patients with ‘tentative re-infections",infection,infection,,1,1,1,1,3,15,93,,,,0.91,0.87,0.93,2,30,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,12,Rennert L,CID- previous infection immunity in university student population,https://academic.oup.com/cid/article/74/4/719/6276528?login=false,102,102,United States,1,Ancestral,mixed variant,,infection,,infection,infection,,1,1,1,1,3,18,24,,,,0.84,0.78,0.88,2,18,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,13,Sheehan M,CID- previous infection immunity ,https://academic.oup.com/cid/article/73/10/1882/6170939?login=true,102,102,United States,1,Ancestral,Ancestral,,infection,retesting and reinfection are defined as occurring ?90 days after initial testing,infection,infection,,1,1,1,1,3,18,80,,,,0.818,0.766,0.858,2,20,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,13,Sheehan M,CID- previous infection immunity ,https://academic.oup.com/cid/article/73/10/1882/6170939?login=true,102,102,United States,1,Ancestral,Ancestral,,"Mild, Moderate + Severe","retesting and reinfection are defined as occurring ?90 days after initial testing. Each test had an indication and presence of symptoms recorded by the ordering provider, which was used to determine if the patient was symptomatic.",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,,,0.845,0.779,0.891,2,20,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,14,Vitale J,Italy previous infection immunity,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2780557,86,86,Italy,1,Ancestral,Ancestral,,infection,Reinfections were defined by a second RT-PCR positivity beyond 90 days after complete resolution of the first infection and with at least 2 consecutive negative test results between episodes,infection,infection,,1,1,1,1,3,18,80,,,,0.94,0.92,0.95,2,34,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,15,Wilkins J,US previous infection immunity HCWs,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438416/,102,102,United States,1,Ancestral,Ancestral,,infection,Possible reinfection cases in participants who were seropositive at baseline were adjudicated by EHR review,infection,infection,,1,1,1,1,3,18,60,,,,0.74,0.47,0.87,0,,,,,,Antibody testing,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 60.,han20
,0,16,Letizia A,US previous infection immunity,https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00158-2/fulltext,102,102,United States,1,Ancestral,Ancestral,,infection,,infection,infection,,1,1,1,1,3,18,20,,,,0.84,0.75,0.9,0,,,,,,Antibody testing,Good,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,17,Abo-Leyah H,UL previous infection immunity HCWs,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164012/,95,95,United Kingdom,1,Ancestral,Ancestral,,"Mild, Moderate + Severe",symptomatic SARS-CoV-2 infections,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,60,,,,0.85,0.65,0.94,2,11,,,,,Antibody testing,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 60. ,han20
,0,18,Lumley S,UK previous infection immunity alpha,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab608/6314286?login=false,95,95,United Kingdom,1,Ancestral,B.1.1.7,,"Mild, Moderate + Severe",symptomatic SARS-CoV-2 infections,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,,,,,,0.98,0.82,0.99,0,,,,,,Antibody testing,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age range not specified,han20
,0,18,Lumley S,UK previous infection immunity alpha,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab608/6314286?login=false,95,95,United Kingdom,1,Ancestral,B.1.1.7,,infection,PCR-confirmed symptomatic SARS-CoV-2 infection,infection,infection,,1,1,1,1,3,,,,,,0.86,0.74,0.93,0,,,,,,Antibody testing,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age range not specified,han20
,0,19,Breathnach A,UK previous infection immunity,https://www.journalofinfection.com/article/S0163-4453(21)00010-4/fulltext,95,95,United Kingdom,1,Ancestral,Ancestral,,infection,Cases where the second positive result was >/= 90 days after the first,infection,infection,,1,1,1,1,3,,,,,,0.94,0.88,0.97,2,32,,,,,Antibody testing and/or confirmed infection through PCR,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age range not specified,han20
,0,20,Manica M,Italy previous infection immunity,https://www.medrxiv.org/content/10.1101/2021.04.14.21255502v1.full.pdf,86,86,Italy,1,Ancestral,Ancestral,,"Mild, Moderate + Severe","Symptomatic infections were defined as positive participants having fever and either cough or at least two of the following symptoms: widespread myalgia, headache, dyspnoea, pharyngodynia, diarrhea, nausea/vomiting, anosmia/ageusia, asthenia",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,,,,,,0.946,0.831,0.991,0,,,,,,Antibody testing,Poor,0,0,0,0,0,0,0,0,0,0,0,0,Age range not specified,han20
,0,21,Leidi A,Swiss previous infection immunity,https://academic.oup.com/cid/article/74/4/622/6287116?login=false,94,94,Switzerland,1,Ancestral,Ancestral,,infection,"virologically confirmed SARS-CoV-2 infection during the study period, defined by the time between inclusion (date of blood sample collection for serology) and death or the end of the study",infection,infection,,1,1,1,1,3,12,80,,,,0.94,0.86,0.98,0,,,,,,Antibody testing,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >=  80.,han20
,0,22,Pouwels K,Nature- UK VE Delta,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,1,Ancestral,B.1.1.7,,"Mild, Moderate + Severe",RT–PCR positivity and split according to self-reported symptoms,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,,,0.8,0.75,0.84,0,,,,,,Antibody testing and/or confirmed infection through PCR,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age is 18+ included as 18-80 for analysis,han20
,0,22,Pouwels K,Nature- UK VE Delta,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,1,Ancestral,B.1.1.7,,infection,positive pcr for covid 19 regardless of symptoms,infection,infection,,1,1,1,1,3,18,80,,,,0.6,0.5,0.68,0,,,,,,Antibody testing and/or confirmed infection through PCR,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age is 18+ included as 18-80 for analysis,han20
,0,22,Pouwels K,Nature- UK VE Delta,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,1,"Ancestral, B.1.1.7",B.1.617.2,,"Mild, Moderate + Severe",RT–PCR positivity and split according to self-reported symptoms,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,,,0.82,0.73,0.88,0,,,,,,Antibody testing and/or confirmed infection through PCR,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age is 18+ included as 18-80 for analysis,han20
,0,22,Pouwels K,Nature- UK VE Delta,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,1,"Ancestral, B.1.1.7",B.1.617.2,,infection,positive pcr for covid 19 regardless of symptoms,infection,infection,,1,1,1,1,3,18,80,,,,0.72,0.58,0.82,0,,,,,,Antibody testing and/or confirmed infection through PCR,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age is 18+ included as 18-80 for analysis,han20
,0,23,Pritchard E,Nature- UK VE Alpha,https://www.nature.com/articles/s41591-021-01410-w#Fig3,95,95,United Kingdom,1,"Ancestral, B.1.1.7","Ancestral, B.1.1.7",,infection,a PCR-positive test after four or more consecutive negative tests; or a PCR-positive test at least 90?d after the start of a previous infection episode,infection,infection,,1,1,1,1,3,18,80,,,,0.28,0.1,0.43,1,,0,15,0_15,Weeks after infection,Antibody testing and/or confirmed infection through PCR,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age is 18+ included as 18-80 for analysis,han20
,0,23,Pritchard E,Nature- UK VE Alpha,https://www.nature.com/articles/s41591-021-01410-w#Fig3,95,95,United Kingdom,1,"Ancestral, B.1.1.7","Ancestral, B.1.1.7",,infection,a PCR-positive test after four or more consecutive negative tests; or a PCR-positive test at least 90?d after the start of a previous infection episode,infection,infection,,1,1,1,1,3,18,80,,,,0.7,0.56,0.79,1,,16,32,16_32,Weeks after infection,Antibody testing and/or confirmed infection through PCR,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age is 18+ included as 18-80 for analysis,han20
,0,23,Pritchard E,Nature- UK VE Alpha,https://www.nature.com/articles/s41591-021-01410-w#Fig3,95,95,United Kingdom,1,"Ancestral, B.1.1.7","Ancestral, B.1.1.7",,"Mild, Moderate + Severe",a PCR-positive test after four or more consecutive negative tests; or a PCR-positive test at least 90?d after the start of a previous infection episode (with self reported symptoms),Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,,,0.67,0.5,0.88,1,,0,15,0_15,Weeks after infection,Antibody testing and/or confirmed infection through PCR,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age is 18+ included as 18-80 for analysis,han20
,0,23,Pritchard E,Nature- UK VE Alpha,https://www.nature.com/articles/s41591-021-01410-w#Fig3,95,95,United Kingdom,1,"Ancestral, B.1.1.7","Ancestral, B.1.1.7",,"Mild, Moderate + Severe",a PCR-positive test after four or more consecutive negative tests; or a PCR-positive test at least 90?d after the start of a previous infection episode (with self reported symptoms),Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,,,0.95,0.85,0.985,1,,16,32,16_32,Weeks after infection,Antibody testing and/or confirmed infection through PCR,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age is 18+ included as 18-80 for analysis,han20
,0,23,Pritchard E,Nature- UK VE Alpha,https://www.nature.com/articles/s41591-021-01410-w#Fig3,95,95,United Kingdom,1,"Ancestral, B.1.1.7",B.1.1.7,,infection,a PCR-positive test after four or more consecutive negative tests; or a PCR-positive test at least 90?d after the start of a previous infection episode. positive infection episodes were classified as compatible with the B.1.1.7 SARS-CoV-2 variant (those positive at least once for ORF1ab?+?N across the episode and never S positive,infection,infection,,1,1,1,1,3,18,80,,,,0.42,0.19,0.58,1,,0,15,0_15,Weeks after infection,Antibody testing and/or confirmed infection through PCR,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age is 18+ included as 18-80 for analysis,han20
,0,23,Pritchard E,Nature- UK VE Alpha,https://www.nature.com/articles/s41591-021-01410-w#Fig3,95,95,United Kingdom,1,"Ancestral, B.1.1.7",B.1.1.7,,infection,a PCR-positive test after four or more consecutive negative tests; or a PCR-positive test at least 90?d after the start of a previous infection episode. positive infection episodes were classified as compatible with the B.1.1.7 SARS-CoV-2 variant (those positive at least once for ORF1ab?+?N across the episode and never S positive,infection,infection,,1,1,1,1,3,18,80,,,,0.81,0.66,0.9,1,,16,32,16_32,Weeks after infection,Antibody testing and/or confirmed infection through PCR,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age is 18+ included as 18-80 for analysis,han20
,0,24,Wang X,medrix- US previous infection immunity,https://www.medrxiv.org/content/10.1101/2022.03.24.22272901v1.full.pdf,102,102,United States,1,mixed variant,B.1.617.2,,infection,a positive COVID-19 pcr regardless of symptoms or severity,infection,infection,,1,1,1,1,3,18,65,,,,0.87,0.85,0.89,0,,,,,,Unspecified,Poor,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <65, Age end >= 65.",han20
,0,24,Wang X,medrix- US previous infection immunity,https://www.medrxiv.org/content/10.1101/2022.03.24.22272901v1.full.pdf,102,102,United States,1,mixed variant,B.1.1.529,,infection,a positive COVID-19 pcr regardless of symptoms or severity,infection,infection,,1,1,1,1,3,18,65,,,,0.39,0.36,0.42,0,,,,,,Unspecified,Poor,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <65, Age end >= 65.",han20
,0,25,Willett B,medrix- Scotland VE omicron vs Delta,https://www.medrxiv.org/content/10.1101/2022.01.03.21268111v2.full.pdf,434,434,Scotland,1,mixed variant,B.1.617.2,,infection,"confirmed S gene target failure (SGTF), allele specific PCR, and Pango lineage assignments from the sequencing data. SGTF samples with Delta lineage assignments were assigned as Delta infections. Samples for which the sequencing date was more than two weeks away from the first positive PCR were removed from the analysis.",infection,,,1,1,1,1,3,18,108,,,,0.774,0.715,0.823,0,,,,,,Antibody testing,Poor,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,25,Willett B,medrix- Scotland VE omicron vs Delta,https://www.medrxiv.org/content/10.1101/2022.01.03.21268111v2.full.pdf,434,434,Scotland,1,mixed variant,B.1.1.529,,infection,"confirmed S gene target failure (SGTF), allele specific PCR, and Pango lineage assignments from the sequencing data. SGTF samples with Delta lineage assignments were assigned as Delta infections. Samples for which the sequencing date was more than two weeks away from the first positive PCR were removed from the analysis.",infection,,,1,1,1,1,3,18,108,,,,0.339,0.236,0.431,0,,,,,,Antibody testing,Poor,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,26,Altarawneh H ,medrix- Qatar previous infection immunity BA.1 vs BA.2,https://www.nejm.org/doi/full/10.1056/NEJMoa2203965,151,151,Qatar,1,mixed variant,B.1.1.529,,"Mild, Moderate + Severe",Symptomatic SARS-CoV-2 reinfection is conventionally defined as a documented infection ?90 days after an earlier infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,,,0.508,0.454,0.557,2,46,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end 70+",han20
,0,26,Altarawneh H ,medrix- Qatar previous infection immunity BA.1 vs BA.2,https://www.nejm.org/doi/full/10.1056/NEJMoa2203965,151,151,Qatar,1,mixed variant,B.1.1.529.1,,"Mild, Moderate + Severe",Symptomatic SARS-CoV-2 reinfection is conventionally defined as a documented infection ?90 days after an earlier infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,,,0.505,0.381,0.599,2,46,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end 70+",han20
,0,26,Altarawneh H ,medrix- Qatar previous infection immunity BA.1 vs BA.2,https://www.nejm.org/doi/full/10.1056/NEJMoa2203965,151,151,Qatar,1,mixed variant,B.1.1.529.2,,"Mild, Moderate + Severe",Symptomatic SARS-CoV-2 reinfection is conventionally defined as a documented infection ?90 days after an earlier infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,,,0.461,0.395,0.519,2,46,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end 70+",han20
,0,26,Altarawneh H ,medrix- Qatar previous infection immunity BA.1 vs BA.2,https://www.nejm.org/doi/full/10.1056/NEJMoa2203965,151,151,Qatar,1,mixed variant,B.1.1.529,,severe,"Classification of COVID-19 case severity, 10 criticality,10 and fatality11 followed World Health Organization guidelines, and assessments were made by trained medical personnel independent of the study investigators and using individual chart reviews, as part of a national protocol applied to every hospitalized COVID-19 patient",hosp,severe,,1,0,0,0,3,20,70,,,,0.716,0.157,0.904,2,46,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end 70+",han20
,1,26,Altarawneh H ,medrix- Qatar previous infection immunity BA.1 vs BA.2,https://www.nejm.org/doi/full/10.1056/NEJMoa2203965,151,151,Qatar,1,mixed variant,B.1.1.529.1,,severe,"Classification of COVID-19 case severity, 10 criticality,10 and fatality11 followed World Health Organization guidelines, and assessments were made by trained medical personnel independent of the study investigators and using individual chart reviews, as part of a national protocol applied to every hospitalized COVID-19 patient",hosp,severe,,1,0,0,0,3,20,70,,,,0.99,NA,NA,2,46,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end 70+",han20
,0,26,Altarawneh H ,medrix- Qatar previous infection immunity BA.1 vs BA.2,https://www.nejm.org/doi/full/10.1056/NEJMoa2203965,151,151,Qatar,1,mixed variant,B.1.1.529.2,,severe,"Classification of COVID-19 case severity, 10 criticality,10 and fatality11 followed World Health Organization guidelines, and assessments were made by trained medical personnel independent of the study investigators and using individual chart reviews, as part of a national protocol applied to every hospitalized COVID-19 patient",hosp,severe,,1,0,0,0,3,20,70,,,,0.734,0.002,0.929,2,46,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end 70+",han20
,0,27,Starrfelt J,medrix- Norway Delta VE,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,1,mixed variant,B.1.617.2,,infection,SARS-CoV-2 re-infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry 180 after 1st infection,infection,infection,,1,1,1,1,3,18,85,,,,0.931,0.923,0.939,0,,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,28,Cerqueira-Silva T,medrix- Brazil previous infection immunity,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00288-2/fulltext,135,135,Brazil,1,mixed variant,B.1.1.529,,"Mild, Moderate + Severe",Cases of confirmed infection were defined as adults with a positive SARS-CoV-2 RT–PCR or Lateral-flow test. sample collected within ten days of symptom onset,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,,,0.289,0.269,0.309,0,,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 65,han20
,0,28,Cerqueira-Silva T,medrix- Brazil previous infection immunity,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00288-2/fulltext,135,135,Brazil,1,mixed variant,B.1.1.529,,severe,Hospital admission up to 14 days after a positive test or a positive test within <72 hours of hospital admission. Mortality outcome was defined as death occurring within 28 days after a positive test,hosp&death,severe,,1,0,0,0,3,18,65,,,,0.856,0.827,0.88,0,,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 65,han20
,0,28,Cerqueira-Silva T,medrix- Brazil previous infection immunity,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00288-2/fulltext,135,135,Brazil,1,mixed variant,B.1.1.529,,severe,Hospital admission up to 14 days after a positive test or a positive test within <72 hours of hospital admission. Mortality outcome was defined as death occurring within 28 days after a positive test,hosp&death,severe,,1,0,0,0,3,18,65,,,,0.845,0.731,0.911,1,,12,23,12_23,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age end >= 65, end was > 1 year, interval added as 52-64 for sake of the analysis",han20
,0,28,Cerqueira-Silva T,medrix- Brazil previous infection immunity,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00288-2/fulltext,135,135,Brazil,1,mixed variant,B.1.1.529,,severe,Hospital admission up to 14 days after a positive test or a positive test within <72 hours of hospital admission. Mortality outcome was defined as death occurring within 28 days after a positive test,hosp&death,severe,,1,0,0,0,3,18,65,,,,0.895,0.86,0.922,1,,24,51,24_51,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age end >= 65, end was > 1 year, interval added as 52-64 for sake of the analysis",han20
,0,28,Cerqueira-Silva T,medrix- Brazil previous infection immunity,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00288-2/fulltext,135,135,Brazil,1,mixed variant,B.1.1.529,,severe,Hospital admission up to 14 days after a positive test or a positive test within <72 hours of hospital admission. Mortality outcome was defined as death occurring within 28 days after a positive test,hosp&death,severe,,1,0,0,0,3,18,65,,,,0.803,0.744,0.848,1,,52,64,52_64,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age end >= 65, end was > 1 year, interval added as 52-64 for sake of the analysis",han20
,0,28,Cerqueira-Silva T,medrix- Brazil previous infection immunity,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00288-2/fulltext,135,135,Brazil,1,mixed variant,B.1.1.529,,"Mild, Moderate + Severe",Cases of confirmed infection were defined as adults with a positive SARS-CoV-2 RT–PCR or Lateral-flow test. sample collected within ten days of symptom onset,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,,,0.528,0.483,0.568,1,,12,23,12_23,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age end >= 65, end was > 1 year, interval added as 52-64 for sake of the analysis",han20
,0,28,Cerqueira-Silva T,medrix- Brazil previous infection immunity,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00288-2/fulltext,135,135,Brazil,1,mixed variant,B.1.1.529,,"Mild, Moderate + Severe",Cases of confirmed infection were defined as adults with a positive SARS-CoV-2 RT–PCR or Lateral-flow test. sample collected within ten days of symptom onset,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,,,0.327,0.302,0.352,1,,24,51,24_51,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age end >= 65, end was > 1 year, interval added as 52-64 for sake of the analysis",han20
,0,28,Cerqueira-Silva T,medrix- Brazil previous infection immunity,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00288-2/fulltext,135,135,Brazil,1,mixed variant,B.1.1.529,,"Mild, Moderate + Severe",Cases of confirmed infection were defined as adults with a positive SARS-CoV-2 RT–PCR or Lateral-flow test. sample collected within ten days of symptom onset,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,,,0.147,0.108,0.185,1,,52,64,52_64,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age end >= 65, end was > 1 year, interval added as 52-64 for sake of the analysis",han20
,0,29,Carazo S,medrix- previous infection immunity Canada,https://www.medrxiv.org/content/10.1101/2022.04.29.22274455v2.full.pdf,101,101,Canada,1,mixed variant,B.1.1.529,,infection,Reinfection was defined as the first SARS-CoV-2 positive result during the study period identified ?90 days after a primary infection,infection,infection,,1,1,1,1,3,12,70,,,,0.44,0.38,0.48,0,,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 70,han20
,0,29,Carazo S,medrix- previous infection immunity Canada,https://www.medrxiv.org/content/10.1101/2022.04.29.22274455v2.full.pdf,101,101,Canada,1,Ancestral,B.1.1.529,,infection,Reinfection was defined as the first SARS-CoV-2 positive result during the study period identified ?90 days after a primary infection,infection,infection,,1,1,1,1,3,12,70,,,,0.29,0.2,0.37,0,,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 70,han20
,0,29,Carazo S,medrix- previous infection immunity Canada,https://www.medrxiv.org/content/10.1101/2022.04.29.22274455v2.full.pdf,101,101,Canada,1,B.1.1.7,B.1.1.529,,infection,Reinfection was defined as the first SARS-CoV-2 positive result during the study period identified ?90 days after a primary infection,infection,infection,,1,1,1,1,3,12,70,,,,0.44,0.26,0.57,0,,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 70,han20
,0,29,Carazo S,medrix- previous infection immunity Canada,https://www.medrxiv.org/content/10.1101/2022.04.29.22274455v2.full.pdf,101,101,Canada,1,B.1.617.2,B.1.1.529,,infection,Reinfection was defined as the first SARS-CoV-2 positive result during the study period identified ?90 days after a primary infection,infection,infection,,1,1,1,1,3,12,70,,,,0.67,0.57,0.75,0,,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 70,han20
,0,29,Carazo S,medrix- previous infection immunity Canada,https://www.medrxiv.org/content/10.1101/2022.04.29.22274455v2.full.pdf,101,101,Canada,1,mixed variant,B.1.1.529,,severe,"COVID-19 hospitalization, defined by admission ?24-hours and within 14 days of a SARS-CoV-2 positive specimen, was also assessed",hosp,severe,,1,1,1,1,3,12,70,,,,0.81,0.66,0.89,0,,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 70,han20
,0,29,Carazo S,medrix- previous infection immunity Canada,https://www.medrxiv.org/content/10.1101/2022.04.29.22274455v2.full.pdf,101,101,Canada,1,mixed variant,B.1.1.529,,infection,Reinfection was defined as the first SARS-CoV-2 positive result during the study period identified ?90 days after a primary infection,infection,infection,,1,1,1,1,3,12,70,,,,0.66,0.57,0.73,1,,12,23,12_23,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 70,han20
,0,29,Carazo S,medrix- previous infection immunity Canada,https://www.medrxiv.org/content/10.1101/2022.04.29.22274455v2.full.pdf,101,101,Canada,1,mixed variant,B.1.1.529,,infection,Reinfection was defined as the first SARS-CoV-2 positive result during the study period identified ?90 days after a primary infection,infection,infection,,1,1,1,1,3,12,70,,,,0.49,0.32,0.61,1,,24,35,24_35,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 70,han20
,0,29,Carazo S,medrix- previous infection immunity Canada,https://www.medrxiv.org/content/10.1101/2022.04.29.22274455v2.full.pdf,101,101,Canada,1,Ancestral,B.1.1.529,,infection,Reinfection was defined as the first SARS-CoV-2 positive result during the study period identified ?90 days after a primary infection,infection,infection,,1,1,1,1,3,12,70,,,,0.35,0.21,0.47,1,,36,47,36_47,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 70,han20
,0,29,Carazo S,medrix- previous infection immunity Canada,https://www.medrxiv.org/content/10.1101/2022.04.29.22274455v2.full.pdf,101,101,Canada,1,B.1.617.2,B.1.1.529,,infection,Reinfection was defined as the first SARS-CoV-2 positive result during the study period identified ?90 days after a primary infection,infection,infection,,1,1,1,1,3,12,70,,,,0.29,0.17,0.38,1,,48,75,48_75,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 70,han20
,0,29,Carazo S,medrix- previous infection immunity Canada,https://www.medrxiv.org/content/10.1101/2022.04.29.22274455v2.full.pdf,101,101,Canada,1,B.1.1.7,B.1.1.529,,infection,Reinfection was defined as the first SARS-CoV-2 positive result during the study period identified ?90 days after a primary infection,infection,infection,,1,1,1,1,3,12,70,,,,0.27,0.08,0.42,1,,76,96,76_96,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age end >= 70,han20
,1,30,Pulliam J,medrix- South Africa SACEMA previous immunity infection,https://www.medrxiv.org/content/10.1101/2021.11.11.21266068v2.full.pdf,196,196,South Africa,1,Ancestral,B.1.351,,infection,"reinfection is positive test associated with an individual’s first identified infection
(i.e., within 90 days of a previous positive test",infection,infection,,1,1,1,1,3,,,,,,,,,0,,,,,,,,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,1,30,Pulliam J,medrix- South Africa SACEMA previous immunity infection,https://www.medrxiv.org/content/10.1101/2021.11.11.21266068v2.full.pdf,196,196,South Africa,1,Ancestral,B.1.617.2,,infection,"reinfection is positive test associated with an individual’s first identified infection
(i.e., within 90 days of a previous positive test",infection,infection,,1,1,1,1,3,,,,,,,,,0,,,,,,,,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,1,30,Pulliam J,medrix- South Africa SACEMA previous immunity infection,https://www.medrxiv.org/content/10.1101/2021.11.11.21266068v2.full.pdf,196,196,South Africa,1,Ancestral,B.1.1.529,,infection,"reinfection is positive test associated with an individual’s first identified infection
(i.e., within 90 days of a previous positive test",infection,infection,,1,1,1,1,3,,,,,,,,,0,,,,,,,,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,31,Nordstrom P,Lancet- previous infection immunity ,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00143-8/fulltext,93,93,Sweden,1,mixed variant,mixed variant,,infection,SARS-CoV-2 infection of any severity for the present study,infection,infection,,1,1,1,1,3,,,,,,0.48,0.47,0.48,1,,2,12,2_12,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,interval end at >9 months included as 37-48.,han20
,0,31,Nordstrom P,Lancet- previous infection immunity ,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00143-8/fulltext,93,93,Sweden,1,mixed variant,mixed variant,,infection,SARS-CoV-2 infection of any severity for the present study,infection,infection,,1,1,1,1,3,,,,,,0.96,0.95,0.96,1,,13,24,13_24,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,interval end at >9 months included as 37-48.,han20
,0,31,Nordstrom P,Lancet- previous infection immunity ,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00143-8/fulltext,93,93,Sweden,1,mixed variant,mixed variant,,infection,SARS-CoV-2 infection of any severity for the present study,infection,infection,,1,1,1,1,3,,,,,,0.92,0.91,0.93,1,,25,36,25_36,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,interval end at >9 months included as 37-48.,han20
,0,31,Nordstrom P,Lancet- previous infection immunity ,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00143-8/fulltext,93,93,Sweden,1,mixed variant,mixed variant,,infection,SARS-CoV-2 infection of any severity for the present study,infection,infection,,1,1,1,1,3,,,,,,0.93,0.92,0.98,1,,37,48,37_48,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,interval end at >9 months included as 37-48.,han20
,1,31,Nordstrom P,Lancet- previous infection immunity ,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00143-8/fulltext,93,93,Sweden,1,mixed variant,mixed variant,,severe," inpatient hospitalisation with COVID-19 as the main diagnosis and reason for admission, traced using the National Inpatient Register and the International Classification of Disease (ICD) version 10 code U071",hosp,severe,,1,1,1,0,3,,,,,,NA ,NA,NA,1,,2,12,2_12,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,interval end at >9 months included as 37-48.,han20
,0,31,Nordstrom P,Lancet- previous infection immunity ,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00143-8/fulltext,93,93,Sweden,1,mixed variant,mixed variant,,severe," inpatient hospitalisation with COVID-19 as the main diagnosis and reason for admission, traced using the National Inpatient Register and the International Classification of Disease (ICD) version 10 code U072",hosp,severe,,1,1,1,0,3,,,,,,0.89,0.86,0.91,1,,13,24,13_24,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,interval end at >9 months included as 37-48.,han20
,0,31,Nordstrom P,Lancet- previous infection immunity ,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00143-8/fulltext,93,93,Sweden,1,mixed variant,mixed variant,,severe," inpatient hospitalisation with COVID-19 as the main diagnosis and reason for admission, traced using the National Inpatient Register and the International Classification of Disease (ICD) version 10 code U073",hosp,severe,,1,1,1,0,3,,,,,,0.85,0.09,0.78,1,,25,36,25_36,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,interval end at >9 months included as 37-48.,han20
,0,31,Nordstrom P,Lancet- previous infection immunity ,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00143-8/fulltext,93,93,Sweden,1,mixed variant,mixed variant,,severe," inpatient hospitalisation with COVID-19 as the main diagnosis and reason for admission, traced using the National Inpatient Register and the International Classification of Disease (ICD) version 10 code U074",hosp,severe,,1,1,1,0,3,,,,,,0.78,0.085,0.66,1,,37,48,37_48,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,interval end at >9 months included as 37-48.,han20
,0,32,ONS,ONS- report of reinfection probablity ,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveycharacteristicsofpeopletestingpositiveforcovid19uk/25august2021,95,95,United Kingdom,1,mixed variant,mixed variant,,infection,"define reinfection as a new positive test 120 days or more after an initial first positive test which was preceded by at least one negative test, or where an individual has had a subsequent positive test following four consecutive negative tests regardless of the time since the first positive",infection,infection,,1,1,1,1,3,,,,,,0.909,0.894,0.92,0,,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,33,Imperial College,UKHSA and NHS data for previous infection immunity against reinfection,https://www.imperial.ac.uk/news/232698/omicron-largely-evades-immunity-from-past/,95,95,United Kingdom,1,mixed variant,B.1.1.529,,infection,,infection,infection,,1,1,1,1,3,,,,,,0.19,0,0.27,0,,,,,,Confirmed infection registered in National Health System,NA,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,34,Jeffery-Smith A,Eurosurveillance- Uk previous infection immunity,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863231/,95,95,United Kingdom,1,Ancestral,Ancestral,,infection,"A re-infection was defined as an individual testing SARS-CoV-2 RT-PCR positive while having evidence of previous seropositivity by any assay, or a previous RT-PCR-positive result more than 90 days earlier in an individual without serological analysis (assumed to have seroconverted)",infection,infection,,1,1,1,1,3,,,,,,0.96,0.79,0.99,0,,,,,,Antibody testing and/or confirmed infection through PCR,Poor,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,35,Gallias F,France previous infection immunity,https://www.sciencedirect.com/science/article/pii/S2352396421003546,80,80,France,1,Ancestral,mixed variant,,infection,"SARS-CoV-2 infection/reinfection was documented by RT-PCR or serological testing among COVID-19 negative and positive HCW, respectively",infection,infection,,1,1,1,1,3,,,,,,0.97,0.76,0.99,0,,,,,,Antibody testing and/or confirmed infection through PCR,Fair,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,36,Krutikov M,Lancet- LTC previous infection immunity,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175048/,95,95,United Kingdom,1,Ancestral,mixed variant,,infection,positive pcr in people with a positive antibody test,infection,infection,,1,1,1,1,3,18,64,,,,0.61,0.18,0.81,0,,,,,,Antibody testing,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age start <65,han20
,0,36,Krutikov M,Lancet- LTC previous infection immunity,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175048/,95,95,United Kingdom,1,Ancestral,mixed variant,,infection,positive pcr in people with a positive antibody test,infection,infection,,1,1,1,1,3,65,90,,,,0.85,0.56,0.95,0,,,,,,Antibody testing,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >=65,han20
,0,37,Harvey R,JAMA- previous infection immunity,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905701/,102,102,United States,1,Ancestral,Ancestral,,infection,positive NAAT in patients with positive antiboy testing,infection,infection,,1,1,1,1,3,,,,,,0.9,0.89,0.91,0,,,,,,Antibody testing,Poor,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,38,Maier H,CID- previous infection protection from reinfection,https://www-ncbi-nlm-nih-gov.offcampus.lib.washington.edu/pmc/articles/PMC8499752/,102,102,United States,1,mixed variant,mixed variant,,infection,"defined as seropositive participants who reported a COVID-19–related illness: (1) during the first epidemic (March–August 2020) as determined by RT-PCR results; (2) associated with a positive RT-PCR test; or (3) had an epidemiological connection; namely, someone in their household tested positive by RT-PCR",infection,infection,,1,1,1,1,3,0,96,,,,0.883,0.48,0.974,0,,,,,,Antibody testing,Fair,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,38,Maier H,CID- previous infection protection from reinfection,https://www-ncbi-nlm-nih-gov.offcampus.lib.washington.edu/pmc/articles/PMC8499752/,102,102,United States,1,mixed variant,mixed variant,,"Mild, Moderate + Severe","Mild cases reported loss of smell or taste or exhibited ?2 COVID-19–related manifestations. Moderate cases reported rapid or difficulty breathing, shortness of breath, chest pain or tightness in the chest, had an outpatient hospital visit, or self-reported their disease severity as moderate or severe. Severe cases were admitted to the hospital or self-reported their disease severity as very severe",Symptomatic,"Mild, Moderate + Severe",,1,1,1,1,3,0,96,,,,0.936,0.511,0.992,0,,,,,,Antibody testing,Fair,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,39,Chemaitelly H,medrix- Omicron sublineage protection against other omicron sublineage,https://www.medrxiv.org/content/10.1101/2022.02.24.22271440v1.full.pdf,151,151,Qatar,1,B.1.1.529.1,B.1.1.529.2,,infection,,infection,infection,,1,1,1,1,3,0,70,,,,0.949,0.884,0.978,0,,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >=70.,han20
,0,39,Chemaitelly H,medrix- Omicron sublineage protection against other omicron sublineage,https://www.medrxiv.org/content/10.1101/2022.02.24.22271440v1.full.pdf,151,151,Qatar,1,B.1.1.529.2,B.1.1.529.1,,infection,,infection,infection,,1,1,1,1,3,0,70,,,,0.856,0.774,0.909,0,,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,Age end >=70.,han20
,0,40,Satwik R,EJIM- India Astrazeneca Delta VE,https://www.ejinme.com/article/S0953-6205(21)00271-5/fulltext,163,163,India,1,mixed variant,B.1.617.2,,"Mild, Moderate + Severe",,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,,,,,,0.93,0.87,0.96,2,38,,,,,Unspecified,Fair,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,41,Chin E,medrix- previous infection protection,https://www.medrxiv.org/content/10.1101/2022.05.26.22275639v1.full.pdf,102,102,United States,1,mixed variant,B.1.1.529,,infection,positive real-time PCR or antigen diagnostic test for SARS-CoV-2 90 days after a previous infection,infection,infection,,1,1,1,1,3,18,55,,,,0.257,0.234,0.316,2,59,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age end >=55.,han20
,0,41,Chin E,medrix- previous infection protection,https://www.medrxiv.org/content/10.1101/2022.05.26.22275639v1.full.pdf,102,102,United States,1,B.1.617.2,B.1.1.529,,infection,positive real-time PCR or antigen diagnostic test for SARS-CoV-2 90 days after a previous infection,infection,infection,,1,1,1,1,3,18,55,,,,0.608,0.584,0.668,2,21,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,Age end >=55.,han20
,0,42,Braeye T,Vaccine- previous infection immunity against alpha and delta,https://www.sciencedirect.com/science/article/pii/S0264410X22004418?via%3Dihub,76,76,Belgium,1,mixed variant,B.1.617.2,,infection, A previous SARS-CoV2-infection was defined as having had a positive PCR or antigenic test more than 90 days prior to the date of sampling.,infection,infection,,1,1,1,1,3,0,84,,,,0.79,0.75,0.83,0,,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,42,Braeye T,Vaccine- previous infection immunity against alpha and delta,https://www.sciencedirect.com/science/article/pii/S0264410X22004418?via%3Dihub,76,76,Belgium,1,mixed variant,B.1.1.7,,infection, A previous SARS-CoV2-infection was defined as having had a positive PCR or antigenic test more than 90 days prior to the date of sampling.,infection,infection,,1,1,1,1,3,0,84,,,,0.83,0.8,0.88,0,,,,,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,42,Braeye T,Vaccine- previous infection immunity against alpha and delta,https://www.sciencedirect.com/science/article/pii/S0264410X22004418?via%3Dihub,76,76,Belgium,1,mixed variant,B.1.617.2,,infection, A previous SARS-CoV2-infection was defined as having had a positive PCR or antigenic test more than 90 days prior to the date of sampling.,infection,infection,,1,1,1,1,3,0,84,,,,0.79,0.74,0.83,1,,0,7,0_7,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,42,Braeye T,Vaccine- previous infection immunity against alpha and delta,https://www.sciencedirect.com/science/article/pii/S0264410X22004418?via%3Dihub,76,76,Belgium,1,mixed variant,B.1.617.2,,infection, A previous SARS-CoV2-infection was defined as having had a positive PCR or antigenic test more than 90 days prior to the date of sampling.,infection,infection,,1,1,1,1,3,0,84,,,,0.64,0.61,0.66,1,,21,28,21_28,,Confirmed infection registered in National Health System,Fair,0,0,0,0,0,0,0,0,0,0,0,0,,han20
,0,43,Ayoub H,medrix- previous infection immunity for alpha and beta,https://www.medrxiv.org/content/10.1101/2022.01.02.22268622v1.full.pdf,151,151,Qatar,1,mixed variant,B.1.1.7,,infection,Prior infection was defined as a PCR-confirmed infection ?90 days before a new PCR-positive test,infection,infection,,1,1,1,1,3,20,70,,,,0.97,0.936,0.986,0,,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >-70",han20
,0,43,Ayoub H,medrix- previous infection immunity for alpha and beta,https://www.medrxiv.org/content/10.1101/2022.01.02.22268622v1.full.pdf,151,151,Qatar,1,mixed variant,B.1.351,,infection,Prior infection was defined as a PCR-confirmed infection ?90 days before a new PCR-positive test,infection,infection,,1,1,1,1,3,20,70,,,,0.855,0.824,0.881,0,,,,,,Confirmed infection registered in National Health System,Good,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >-70",han20
,0,44,Chemaitelly H,NEJM- previous infection protection for Alpha and Beta,https://www.nejm.org/doi/10.1056/NEJMc2110300?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed,151,151,Qatar,1,mixed variant,B.1.1.7,,infection,Prior infection was defined as a PCR-confirmed infection ?90 days before a new PCR-positive test,infection,infection,,1,1,1,1,3,20,70,,,,0.964,0.921,0.983,0,,,,,,Antibody testing,Fair,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >-70",han20
,0,44,Chemaitelly H,NEJM- previous infection protection for Alpha and Beta,https://www.nejm.org/doi/10.1056/NEJMc2110300?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed,151,151,Qatar,1,mixed variant,B.1.351,,infection,Prior infection was defined as a PCR-confirmed infection ?90 days before a new PCR-positive test,infection,infection,,1,1,1,1,3,20,70,,,,0.864,0.825,0.895,0,,,,,,Antibody testing,Fair,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <20, Age end >-70",han20
,0,45,Petras M,Pfizer VE Czech cohort study 8 months follow up,https://www.mdpi.com/2076-393X/10/1/9/htm#app1-vaccines-10-00009,47,47,Czechia,1,mixed variant,mixed variant,,infection,all PCR-confirmed COVID-19 infection after 90 days of previous infection,infection,infection,,1,1,1,1,3,30,60,,,,0.925,0.765,0.976,0,,,,,,Confirmed infection registered in National Health System,,0,0,0,0,0,0,0,0,0,0,0,0,"Age start <30, Age end >60",han20
,0,46,Carazo S,medrix- previous omicron or non omicron infection protection against omicron reinfection,https://www.medrxiv.org/content/10.1101/2022.06.23.22276824v1.full.pdf,101,101,Canada,1,mixed variant,B.1.1.529.2,,infection,any SARS-CoV-2 infection or symptomatic infections only (identified by specified testing indication) confirmed by NAAT during the study period determined by Omicron BA.2 subvariant dominance when 86% (60% to 93%) of viruses from sentinel laboratories characterized by sequencing were BA.2,infection,infection,,1,1,1,1,3,18,60,,,,NA,NA,NA,1,,4,7,4_7,,Confirmed infection registered in National Health System,,0,0,0,0,0,0,0,0,0,0,0,0,"Age end >= 60, study peroid ended >12 months included as 52-64 for sake of the analysis",han20
,0,46,Carazo S,medrix- previous omicron or non omicron infection protection against omicron reinfection,https://www.medrxiv.org/content/10.1101/2022.06.23.22276824v1.full.pdf,101,101,Canada,1,mixed variant,B.1.1.529.2,,infection,any SARS-CoV-2 infection or symptomatic infections only (identified by specified testing indication) confirmed by NAAT during the study period determined by Omicron BA.2 subvariant dominance when 86% (60% to 93%) of viruses from sentinel laboratories characterized by sequencing were BA.2,infection,infection,,1,1,1,1,3,18,60,,,,NA,NA,NA,1,,8,11,8_11,,Confirmed infection registered in National Health System,,0,0,0,0,0,0,0,0,0,0,0,0,"Age end >= 60, study peroid ended >12 months included as 52-64 for sake of the analysis",han20
,0,46,Carazo S,medrix- previous omicron or non omicron infection protection against omicron reinfection,https://www.medrxiv.org/content/10.1101/2022.06.23.22276824v1.full.pdf,101,101,Canada,1,mixed variant,B.1.1.529.2,,infection,any SARS-CoV-2 infection or symptomatic infections only (identified by specified testing indication) confirmed by NAAT during the study period determined by Omicron BA.2 subvariant dominance when 86% (60% to 93%) of viruses from sentinel laboratories characterized by sequencing were BA.2,infection,infection,,1,1,1,1,3,18,60,,,,0.42,-0.47,0.77,1,,12,23,12_23,,Confirmed infection registered in National Health System,,0,0,0,0,0,0,0,0,0,0,0,0,"Age end >= 60, study peroid ended >12 months included as 52-64 for sake of the analysis",han20
,0,46,Carazo S,medrix- previous omicron or non omicron infection protection against omicron reinfection,https://www.medrxiv.org/content/10.1101/2022.06.23.22276824v1.full.pdf,101,101,Canada,1,mixed variant,B.1.1.529.2,,infection,any SARS-CoV-2 infection or symptomatic infections only (identified by specified testing indication) confirmed by NAAT during the study period determined by Omicron BA.2 subvariant dominance when 86% (60% to 93%) of viruses from sentinel laboratories characterized by sequencing were BA.2,infection,infection,,1,1,1,1,3,18,60,,,,0.39,0,0.63,1,,24,51,24_51,,Confirmed infection registered in National Health System,,0,0,0,0,0,0,0,0,0,0,0,0,"Age end >= 60, study peroid ended >12 months included as 52-64 for sake of the analysis",han20
,0,46,Carazo S,medrix- previous omicron or non omicron infection protection against omicron reinfection,https://www.medrxiv.org/content/10.1101/2022.06.23.22276824v1.full.pdf,101,101,Canada,1,mixed variant,B.1.1.529.2,,infection,any SARS-CoV-2 infection or symptomatic infections only (identified by specified testing indication) confirmed by NAAT during the study period determined by Omicron BA.2 subvariant dominance when 86% (60% to 93%) of viruses from sentinel laboratories characterized by sequencing were BA.2,infection,infection,,1,1,1,1,3,18,60,,,,0.42,0.17,0.6,1,,52,64,52_64,,Confirmed infection registered in National Health System,,0,0,0,0,0,0,0,0,0,0,0,0,"Age end >= 60, study peroid ended >12 months included as 52-64 for sake of the analysis",han20
,0,46,Carazo S,medrix- previous omicron or non omicron infection protection against omicron reinfection,https://www.medrxiv.org/content/10.1101/2022.06.23.22276824v1.full.pdf,101,101,Canada,1,B.1.1.529.1,B.1.1.529.2,,infection,any SARS-CoV-2 infection or symptomatic infections only (identified by specified testing indication) confirmed by NAAT during the study period determined by Omicron BA.2 subvariant dominance when 86% (60% to 93%) of viruses from sentinel laboratories characterized by sequencing were BA.2,infection,infection,,1,1,1,1,3,18,60,,,,0.82,0.49,0.94,1,,4,7,4_7,,Confirmed infection registered in National Health System,,0,0,0,0,0,0,0,0,0,0,0,0,"Age end >= 60, study peroid ended >12 months included as 52-64 for sake of the analysis",han20
,0,46,Carazo S,medrix- previous omicron or non omicron infection protection against omicron reinfection,https://www.medrxiv.org/content/10.1101/2022.06.23.22276824v1.full.pdf,101,101,Canada,1,B.1.1.529.1,B.1.1.529.2,,infection,any SARS-CoV-2 infection or symptomatic infections only (identified by specified testing indication) confirmed by NAAT during the study period determined by Omicron BA.2 subvariant dominance when 86% (60% to 93%) of viruses from sentinel laboratories characterized by sequencing were BA.2,infection,infection,,1,1,1,1,3,18,60,,,,0.76,0.63,0.85,1,,8,11,8_11,,Confirmed infection registered in National Health System,,0,0,0,0,0,0,0,0,0,0,0,0,"Age end >= 60, study peroid ended >12 months included as 52-64 for sake of the analysis",han20
,0,46,Carazo S,medrix- previous omicron or non omicron infection protection against omicron reinfection,https://www.medrxiv.org/content/10.1101/2022.06.23.22276824v1.full.pdf,101,101,Canada,1,B.1.1.529.1,B.1.1.529.2,,infection,any SARS-CoV-2 infection or symptomatic infections only (identified by specified testing indication) confirmed by NAAT during the study period determined by Omicron BA.2 subvariant dominance when 86% (60% to 93%) of viruses from sentinel laboratories characterized by sequencing were BA.2,infection,infection,,1,1,1,1,3,18,60,,,,0.7,0.61,0.77,1,,12,23,12_23,,Confirmed infection registered in National Health System,,0,0,0,0,0,0,0,0,0,0,0,0,"Age end >= 60, study peroid ended >12 months included as 52-64 for sake of the analysis",han20
,0,46,Carazo S,medrix- previous omicron or non omicron infection protection against omicron reinfection,https://www.medrxiv.org/content/10.1101/2022.06.23.22276824v1.full.pdf,101,101,Canada,1,B.1.1.529.1,B.1.1.529.2,,infection,any SARS-CoV-2 infection or symptomatic infections only (identified by specified testing indication) confirmed by NAAT during the study period determined by Omicron BA.2 subvariant dominance when 86% (60% to 93%) of viruses from sentinel laboratories characterized by sequencing were BA.2,infection,infection,,1,1,1,1,3,18,60,,,,NA,NA,NA,1,,24,51,24_51,,Confirmed infection registered in National Health System,,0,0,0,0,0,0,0,0,0,0,0,0,"Age end >= 60, study peroid ended >12 months included as 52-64 for sake of the analysis",han20
,0,46,Carazo S,medrix- previous omicron or non omicron infection protection against omicron reinfection,https://www.medrxiv.org/content/10.1101/2022.06.23.22276824v1.full.pdf,101,101,Canada,1,B.1.1.529.1,B.1.1.529.2,,infection,any SARS-CoV-2 infection or symptomatic infections only (identified by specified testing indication) confirmed by NAAT during the study period determined by Omicron BA.2 subvariant dominance when 86% (60% to 93%) of viruses from sentinel laboratories characterized by sequencing were BA.2,infection,infection,,1,1,1,1,3,18,60,,,,NA,NA,NA,1,,52,64,52_64,,Confirmed infection registered in National Health System,,0,0,0,0,0,0,0,0,0,0,0,0,"Age end >= 60, study peroid ended >12 months included as 52-64 for sake of the analysis",han20
,0,47,Waxman J,nature- booster dose and infection induced immunity comparison,https://www.nature.com/articles/s41467-022-29858-5#Abs1,85,85,Israel,1,mixed variant,B.1.617.2,,severe,,hosp,severe,,1,0,0,0,3,16,65,,,,0.66,0.5,0.77,0,,,,,,Confirmed infection registered in National Health System,,0,0,0,0,0,0,0,0,0,0,0,0,Age end >=65,han20
